Our group published the very first study to implicate ILC2s in experimental atherosclerosis and atheroprotection by showing that treatment of apoE−/− mice with IL-25 reduced atherosclerosis through the induction of splenic ILC2s, IL-5, B1 cells and anti-phosphorylcholine (PC) IgM antibodies that target oxLDL [25]. This evidence concerns the gene IL25 and atherosclerosis.